tradingkey.logo

Rocket Pharmaceuticals Announces FDA Has Lifted The Clinical Hold On The Pivotal Phase 2 Trial Of Rp-A501 For The Treatment Of Danon Disease

ReutersAug 20, 2025 12:46 PM

- Rocket Pharmaceuticals Inc RCKT.O:

  • ROCKET PHARMACEUTICALS ANNOUNCES FDA HAS LIFTED THE CLINICAL HOLD ON THE PIVOTAL PHASE 2 TRIAL OF RP-A501 FOR THE TREATMENT OF DANON DISEASE

  • ROCKET PHARMACEUTICALS INC - FDA AUTHORIZES STUDY RESUMPTION WITH RECALIBRATED DOSE

  • ROCKET PHARMACEUTICALS- TO WORK WITH INVESTIGATORS TO IMPLEMENT IMMUNOMODULATORY REGIMEN MORE CLOSELY REFLECTING GIVEN IN PHASE 1 PEDIATRIC COHORT

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

Tradingkey
KeyAI